Welcome to Anagrammer Crossword Genius! Keep reading below to see if ipi is an answer to any crossword puzzle or word game (Scrabble, Words With Friends etc). Scroll down to see all the info we have compiled on ipi.
ipi
Searching in Crosswords ...
The answer IPI has 0 possible clue(s) in existing crosswords.
Searching in Word Games ...
The word IPI is NOT valid in any word game. (Sorry, you cannot play IPI in Scrabble, Words With Friends etc)
There are 3 letters in IPI ( I1P3 )
To search all scrabble anagrams of IPI, to go: IPI?
Rearrange the letters in IPI and see some winning combinations
2 letters out of IPI
Searching in Dictionaries ...
Definitions of ipi in various dictionaries:
IPI - Ipilimumab (trade name Yervoy) is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downreg...
Word Research / Anagrams and more ...
Keep reading for additional results and analysis below.
Possible Dictionary Clues |
---|
The long-tailed pangolin (Manis tetradactyla). |
Geographic Matches |
---|
ipi, Republika Srpska, BOSNIA AND HERZEGOWINA |
Ipi, Nusa Tenggara Timur, INDONESIA |
Ipi, Sulawesi Tengah, INDONESIA |
Ipi, Federally Administered Tribal Areas, PAKISTAN |
Ipi might refer to |
---|
Ipilimumab (trade name Yervoy) is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. * Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, an inhibitory mechanism interrupts this destruction. Ipilimumab turns off this inhibitory mechanism and allows CTLs to function.Ipilimumab was approved by the U.S. FDA in 2011 for the treatment of melanoma, a type of skin cancer. It is undergoing clinical trials for the treatment of non-small cell lung carcinoma (NSCLC), small cell lung cancer (SCLC), bladder cancer and metastatic hormone-refractory prostate cancer.The concept of using anti-CTLA4 antibodies to treat cancer was first developed by James P. Allison while he was director of the Cancer Research Laboratory at the University of California, Berkeley. Clinical development of anti-CTLA4 was initiated by Medarex, which was later acquired by Bristol-Myers Squibb. As of 2013 the co |